VSTM Stock Analysis: Verastem | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 395m USD | 12M Return: 3.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Verastem, Inc. (NASDAQ: VSTM) is a development-stage biopharmaceutical company headquartered in Needham, Massachusetts, focused on developing and commercializing oncology therapies in the United States. The companys pipeline is centered on two oral small molecule drug candidates: Avutometinib, a dual RAF/MEK inhibitor designed to target the RAS/MAPK signaling pathway commonly activated in various cancers, and Defactinib, an inhibitor of FAK and proline-rich tyrosine kinase for solid tumors.
Verastem is advancing several clinical programs, including the RAMP 301 confirmatory trial in recurrent low-grade serous ovarian cancer, RAMP 201 evaluating Avutometinib with and without Defactinib, the FRAME study in KRAS mutant cancers, and RAMP 205. The company also has a clinical collaboration with Amgen to test Avutometinib in combination with LUMAKRAS (KRAS-G12C inhibitor) in the RAMP 203 trial, and a discovery partnership with GenFleet Therapeutics targeting RAS pathway-driven cancers. Licensing agreements with Chugai Pharmaceutical (Avutometinib) and Pfizer (FAK inhibitors) support the development and potential commercialization of these assets.
As a small-cap U.S. biotechnology company (GICS Sub Industry: Biotechnology), Verastem operates under a typical development-stage biotech business model: it does not yet generate commercial product revenue and relies on capital markets, partnerships, and licensing deals to fund its research and clinical operations. The combination of multiple licensing and collaboration agreements with larger pharma and biotech partners reflects a common strategy in the sector to share development risk and monetize pipeline assets through milestone payments and potential royalties.
- RAMP 301 Phase 3 readout for ovarian cancer combination
- FDA approval timeline for avutometinib and defactinib NDA
- Cash burn and dilution risk as development-stage biotech
| Net Income: -194.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.67 > 0.02 and ΔFCF/TA 20.58 > 1.0 |
| NWC/Revenue: 274.4% < 20% (prev 371k%; Δ -371k% < -1%) |
| CFO/TA -0.66 > 3% & CFO -150.9m > Net Income -194.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (99.1m) vs 12m ago 83.02% < -2% |
| Gross Margin: 83.75% > 18% (prev -45.83%; Δ 129.6% > 0.5%) |
| Asset Turnover: 27.59% > 50% (prev 0.02%; Δ 27.57% > 0%) |
| Interest Coverage Ratio: -145.3 > 6 (EBIT TTM -192.9m / Interest Expense TTM 1.33m) |
| A: 0.60 (Total Current Assets 202.9m - Total Current Liabilities 66.8m) / Total Assets 227.8m |
| B: -5.27 (Retained Earnings -1.20b / Total Assets 227.8m) |
| C: -1.07 (EBIT TTM -192.9m / Avg Total Assets 179.8m) |
| D: 0.56 (Book Value of Equity 81.8m / Total Liabilities 146.0m) |
| Altman-Z'' = -19.90 = D |
| DSRI: 0.10 (Receivables 10.4m/200k, Revenue 49.6m/24.0k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 2.21 (AQ_t 0.10 / AQ_t-1 0.04) |
| SGI: 2.07k (Revenue 49.6m / 24.0k) |
| TATA: -0.19 (NI -194.0m - CFO -150.9m) / TA 227.8m) |
| Beneish M = 1.48k (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 4.85 with a total of 2,849,557 shares traded. Over the past week, the price has changed by +26.96%, over one month by +32.15%, over three months by -11.01% and over the past year by +3.41%.
Current recommended Stop Loss: 4.20 (which is 13.4% or 2 ATR below the current price).
Verastem has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy VSTM.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 15.1 | 212% |
P/S = 7.9748
P/B = 4.4057
P/EG = -1.89
Revenue TTM = 49.6m USD
EBIT TTM = -192.9m USD
EBITDA TTM = -192.0m USD
Long Term Debt = 76.9m USD (from longTermDebt, last quarter)
Short Term Debt = 6.29m USD (from shortTermDebt, last quarter)
Debt = 88.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 2.81m
Net Debt = -93.4m USD (calculated: Debt 88.3m - CCE 181.7m)
Enterprise Value = 302.0m USD (395.4m + Debt 88.3m - CCE 181.7m)
Interest Coverage Ratio = -145.3 (Ebit TTM -192.9m / Interest Expense TTM 1.33m)
EV/FCF = -1.98x (Enterprise Value 302.0m / FCF TTM -152.3m)
FCF Yield = -50.42% (FCF TTM -152.3m / Enterprise Value 302.0m)
FCF Margin = -307.1% (FCF TTM -152.3m / Revenue TTM 49.6m)
Net Margin = -391.2% (Net Income TTM -194.0m / Revenue TTM 49.6m)
Gross Margin = 83.75% ((Revenue TTM 49.6m - Cost of Revenue TTM 8.06m) / Revenue TTM)
Gross Margin QoQ = 83.66% (prev 83.51%)
Tobins Q-Ratio = 1.33 (Enterprise Value 302.0m / Total Assets 227.8m)
Interest Expense / Debt = 1.50% (Interest Expense 1.33m / Debt 88.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -152.4m (EBIT -192.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.04 (Total Current Assets 202.9m / Total Current Liabilities 66.8m)
Debt / Equity = 1.08 (Debt 88.3m / totalStockholderEquity, last quarter 81.8m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -93.4m / EBITDA -192.0m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -93.4m / FCF TTM -152.3m)
Total Stockholder Equity = 39.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -107.9% (out of range, set to none)
RoE = -486.4% (Net Income TTM -194.0m / Total Stockholder Equity 39.9m)
RoCE = -165.3% (out of range, set to none) (EBIT -192.9m / Capital Employed (Equity 39.9m + L.T.Debt 76.9m))
RoIC = -92.51% (negative operating profit) (NOPAT -152.4m / Invested Capital 164.8m)
WACC = 8.20% (E(395.4m)/V(483.7m) * Re(9.77%) + D(88.3m)/V(483.7m) * Rd(1.50%) * (1-Tc(0.21)))
Discount Rate = 9.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 78.84%
[DCF] Fair Price = unknown (Cash Flow -152.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.11 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.79 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.45 | Chg30d=+0.00% | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.37 | Chg30d=+0.00% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=-1.56 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+33.8% | GrowthRev=+230.9%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+25.5% | GrowthRev=+74.8%
[Analyst] Revisions Ratio: +57% (up=4, down=0)